Trial Profile
Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 Jan 2023 Interim results (at data cut-off: 1 Sep 2022; n=16) presented at the 2023 Gastrointestinal Cancers Symposium.
- 19 Sep 2022 Planned End Date changed from 1 Oct 2023 to 1 Oct 2025.
- 19 Sep 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2024.